Teicoplanin inhibits Ebola pseudovirus infection in cell culture

There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yizhuo, Cui, Rui, Li, Guiming, Gao, Qianqian, Yuan, Shilin, Altmeyer, Ralf, Zou, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113690/
https://www.ncbi.nlm.nih.gov/pubmed/26585243
http://dx.doi.org/10.1016/j.antiviral.2015.11.003
_version_ 1783513726280794112
author Wang, Yizhuo
Cui, Rui
Li, Guiming
Gao, Qianqian
Yuan, Shilin
Altmeyer, Ralf
Zou, Gang
author_facet Wang, Yizhuo
Cui, Rui
Li, Guiming
Gao, Qianqian
Yuan, Shilin
Altmeyer, Ralf
Zou, Gang
author_sort Wang, Yizhuo
collection PubMed
description There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibiting Ebola pseudovirus infection by blocking virus entry in the low micromolar range. Teicoplanin could be evaluated further and incorporated into ongoing clinical studies.
format Online
Article
Text
id pubmed-7113690
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71136902020-04-02 Teicoplanin inhibits Ebola pseudovirus infection in cell culture Wang, Yizhuo Cui, Rui Li, Guiming Gao, Qianqian Yuan, Shilin Altmeyer, Ralf Zou, Gang Antiviral Res Short Communication There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibiting Ebola pseudovirus infection by blocking virus entry in the low micromolar range. Teicoplanin could be evaluated further and incorporated into ongoing clinical studies. Elsevier B.V. 2016-01 2015-11-14 /pmc/articles/PMC7113690/ /pubmed/26585243 http://dx.doi.org/10.1016/j.antiviral.2015.11.003 Text en Copyright © 2015 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Wang, Yizhuo
Cui, Rui
Li, Guiming
Gao, Qianqian
Yuan, Shilin
Altmeyer, Ralf
Zou, Gang
Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title_full Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title_fullStr Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title_full_unstemmed Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title_short Teicoplanin inhibits Ebola pseudovirus infection in cell culture
title_sort teicoplanin inhibits ebola pseudovirus infection in cell culture
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113690/
https://www.ncbi.nlm.nih.gov/pubmed/26585243
http://dx.doi.org/10.1016/j.antiviral.2015.11.003
work_keys_str_mv AT wangyizhuo teicoplanininhibitsebolapseudovirusinfectionincellculture
AT cuirui teicoplanininhibitsebolapseudovirusinfectionincellculture
AT liguiming teicoplanininhibitsebolapseudovirusinfectionincellculture
AT gaoqianqian teicoplanininhibitsebolapseudovirusinfectionincellculture
AT yuanshilin teicoplanininhibitsebolapseudovirusinfectionincellculture
AT altmeyerralf teicoplanininhibitsebolapseudovirusinfectionincellculture
AT zougang teicoplanininhibitsebolapseudovirusinfectionincellculture

Ejemplares similares